<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892682</url>
  </required_header>
  <id_info>
    <org_study_id>UF 9650</org_study_id>
    <nct_id>NCT02892682</nct_id>
  </id_info>
  <brief_title>The Role of the Coagulation Pathways in Recurrent Angioedema</brief_title>
  <acronym>Angiocoag</acronym>
  <official_title>The Role of the Coagulation Pathways in Recurrent Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies reported infraclinical modifications of the homeostasis in chronic
      urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to
      compare groups with isolated wheals, isolated angioedema, combination of both and hereditary
      angioedema in terms of coagulation pathways.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies reported infraclinical modifications of the homeostasis in chronic
      urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to
      compare groups with isolated wheals, isolated angioedema, combination of both and hereditary
      angioedema in terms of coagulation pathways. the main objective is to highlight a difference
      between the rates of different coagulation factors in the 3 groups presenting different
      categories of angiodemes patients with a group of patients with isolated superficial chronic
      urticaria
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of several coagulation pathway markers in each group</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency</condition>
  <arm_group>
    <arm_group_label>Arm 1 AE-Bk</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm of the recurring angiodeme medié by the bradykinine: blood test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 AE-Mast</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 3 AEI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 4 US</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm of superficial nettle rashes: blood test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BLOOD TEST</intervention_name>
    <arm_group_label>Arm 1 AE-Bk</arm_group_label>
    <arm_group_label>Arm 2 AE-Mast</arm_group_label>
    <arm_group_label>ARM 3 AEI</arm_group_label>
    <arm_group_label>ARM 4 US</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent angioderma

        Exclusion Criteria:

          -  anticoagulant therapy, diseases of hemostasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aurélie Du Thanh, MD, Ph D</last_name>
    <phone>33(0)467336937</phone>
    <email>a-du_thanh@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>NADIA raison-Peyron, MD</last_name>
    <phone>+33(0)467336957</phone>
    <email>n-raison@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelie du-Thanh, MD, PhD</last_name>
      <phone>+33(0)467336937</phone>
      <email>a-du_thanh@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nadia Raison-Peyron, MD</last_name>
      <phone>+33 (0) 467336957</phone>
      <email>n-raison@chu-montpellier.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

